Silence Therapeutics plc(SLN)Earnings, Financials & Key RatiosSilence Therapeutics plc (SLN) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's cash position has plummeted to a critical $5.7 million as of 2026Q1, signaling an imminent liquidity crisis that necessitates immediate and potentially dilutive financing.
Silence Therapeutics plc (SLN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Silence Therapeutics plc (SLN) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.32vs $0.33+3.0% | $422,000vs $1M-66.4% |
| Q2 2026 | Mar 5, 2026 | $0.25vs $0.32+21.9% | $39,000vs $3M-98.7% |
| Q4 2025 | Nov 6, 2025 | $0.45vs $0.40-12.5% | $159,000vs $3M-94.9% |
| Q3 2025 | Aug 7, 2025 | $0.54vs $0.27-100.0% | $224,000vs $3M-93.1% |
Recent stock market news and headlines for Silence Therapeutics plc (SLN)
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Silence Therapeutics Plc (NASDAQ:SLN) stock rose Wednesday after Cantor Fitzgerald initiated coverage with an Overweight rating and a positive outlook for its lead drug candidate.
Key metrics vs top competitors for Silence Therapeutics plc (SLN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.15 | $479.42M | -5.37 | -98.71% | -15851.88% | -90.27% | — | |
| $321.59 | $42.91B | 138.02 | 65.19% | 13.46% | 98.29% | — | |
| $86.97 | $12.25B | -7128.69 | 23258.15% | -48.38% | -55.09% | — | |
| $19.79 | $2.09B | -2.78 | 15.58% | 2.98% | 4.89% | — | |
| $17.43 | $1.96B | -4.57 | 16.92% | -597.04% | -57.27% | — | |
| $86.33 | $14.27B | -36.27 | 33.87% | -30.87% | -58.57% | — |
Silence Therapeutics plc (SLN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Silence Therapeutics plc (SLN) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 18, 2026·SEC
May 7, 2026·SEC
Mar 5, 2026·SEC
Get notified when SLN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Silence Therapeutics plc (SLN) stock FAQ — growth, dividends, profitability & financials explained
Silence Therapeutics plc (SLN) reported $0.8M in revenue for fiscal year 2025.
Silence Therapeutics plc (SLN) saw revenue decline by 98.7% over the past year.
Silence Therapeutics plc (SLN) reported a net loss of $75.0M for fiscal year 2025.
Silence Therapeutics plc (SLN) has a return on equity (ROE) of -90.3%. Negative ROE indicates the company is unprofitable.
Silence Therapeutics plc (SLN) had negative free cash flow of $65.7M in fiscal year 2025, likely due to heavy capital investments.
